MET and non-small cell lung carcinoma: Preliminary results of the SAVANNAH trial have demonstrated the beneficial efficacy of osimertinib plus savolitinib in EGFRm NSCLC patients with MET amplified and/or c-MET overexpressed, supporting the results of TATTON study and paving the way for phase III SACHI and SAFFRON study.